Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Provided By GlobeNewswire
Last update: Dec 9, 2024
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial
J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA
Read more at globenewswire.com
